Clinical trial · Interventional
Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions
Early Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions (NUPAN), a Prospective Randomized Interventional Trial
NCT02670265CI-TRIAL-00020738NUPANcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with biliopancreatic tumors are at risk for malnutrition and have to undergo many procedures for diagnostic workup that require fasting periods. In a prospective randomized monocentric study we evaluate the effect of additional parenteral nutrition on weight loss, nutritional status, quality of life and length of hospital stay.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biliary Tract Cancer | Malignant Biliary Tract Neoplasm | ALIAS | 0.90 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
| Weight Loss | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Isotonic fluid (E153) | Dietary Supplement | — | UNRESOLVED |
| Olimel Peri 2.5% ® | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Parenteral nutrition
- description
- Active Comparator: Olimel peri 2.5% ® 1l/d (700 kcal/d) (Baxter GmbH, Unterschleißheim, Germany)
- interventionNames
- Dietary Supplement: Olimel Peri 2.5% ®
- type
- PLACEBO_COMPARATOR
- label
- Isotonic fluid
- description
- Isotonic fluid 1l/d (E153, Berlin-Chemie AG, Berlin, Germany)
- interventionNames
- Dietary Supplement: Isotonic fluid (E153)
Primary outcomes (1)
- measure
- Weight loss
- timeFrame
- ≥ 3 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Hospitalization for suspected biliopancreatic mass lesion * Consent to participate to the study Exclusion Criteria: * Liver cirrhosis (Child-Pugh B and C) * Heart or renal failure (grade III or more) * Dementia * Pregnancy * Hospital stay less than 3 days
References
Publications (1)
- DERIVEDKruger J, Meffert PJ, Vogt LJ, Gartner S, Steveling A, Kraft M, Mayerle J, Lerch MM, Aghdassi AA. Early Parenteral Nutrition in Patients with Biliopancreatic Mass Lesions, a Prospective, Randomized Intervention Trial. PLoS One. 2016 Nov 18;11(11):e0166513. doi: 10.1371/journal.pone.0166513. eCollection 2016. PMID 27861546